Loading...
Celecoxib as a Valuable Adjuvant in Cutaneous Melanoma Treated with Trametinib
Background: Melanoma patients stop responding to targeted therapies mainly due to mitogen activated protein kinase (MAPK) pathway re-activation, phosphoinositide 3 kinase/the mechanistic target of rapamycin (PI3K/mTOR) pathway activation or stromal cell influence. The future of melanoma treatment li...
Na minha lista:
| Udgivet i: | Int J Mol Sci |
|---|---|
| Main Authors: | , , , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
MDPI
2021
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8122835/ https://ncbi.nlm.nih.gov/pubmed/33922284 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/ijms22094387 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|